secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kezar Life Sciences, Inc. (KZR)
CIK:        0001645666
Form:       8-K
Filed at:   2023-06-16T23:59:59+00:00
Accession:  0000950170-23-028600
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 3.03, 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kezar Life Sciences increases authorized shares to 260M following stockholder vote
--------------------------------------------------------------------------------

- Authorized shares raised from 135M to 260M (250M common, 10M preferred) via certificate amendment effective June 14, 2023.
- Stockholders approved the amendment with 65.3M votes for, 0.9M against, 0.1M abstentions.
- Three Class II directors elected: Franklin Berger, Graham Cooper, Micki Klearman, M.D.; all terms until 2026.
- KPMG LLP ratified as independent auditor for fiscal 2023 with 66.2M votes for, 5.2K against, 3.1K abstentions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645666/000095017023028600/0000950170-23-028600-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645666/000095017023028600/kzr-20230614.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-028600

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer